Pacific Biosciences Statistics
Pacific Biosciences (P09) Stock Statistics & Valuation Metrics
Total Valuation
Pacific Biosciences has a market cap or net worth of EUR 523.81M. The enterprise value is EUR 1.24B.
- Market Cap
- EUR 523.81M
- Enterprise Value
- EUR 1.24B
Share Statistics
Pacific Biosciences has 312,926,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 312,926,730
- Owned by Insiders
- 2.75%
- Owned by Institutions
- 67.66%
Financial Efficiency
Pacific Biosciences’s return on equity (ROE) is -102.15 and return on invested capital (ROIC) is -76.37%.
- Return on Equity (ROE)
- -102.15
- Return on Assets (ROA)
- -0.70
- Return on Invested Capital (ROIC)
- -76.37%
- Return on Capital Employed (ROCE)
- -0.76
- Revenue Per Employee
- 329.91K
- Profits Per Employee
- -1.13M
- Employee Count
- 485
- Asset Turnover
- 0.20
- Inventory Turnover
- 2.22
Valuation Ratios
The current PE Ratio of Pacific Biosciences is -4.39. Pacific Biosciences’s PEG ratio is -0.07.
- PE Ratio
- -4.39
- PS Ratio
- 3.57
- PB Ratio
- -9.36
- Price to FCF
- -3.06
- Price to Operating Cash Flow
- -3.16
- PEG Ratio
- -0.07
Income Statement
In the last 12 months, Pacific Biosciences had revenue of 160.00M and earned -546.38M in profits. Earnings per share was -1.82.
- Revenue
- 160.00M
- Gross Profit
- 50.67M
- Operating Income
- -557.56M
- Pretax Income
- -546.06M
- Net Income
- -546.38M
- EBITDA
- -152.69M
- Earnings Per Share (EPS)
- -1.82
Cash Flow
In the last 12 months, operating cash flow was -181.64M and capital expenditures -6.45M, giving a free cash flow of -188.09M billion.
- Operating Cash Flow
- -181.64M
- Free Cash Flow
- -188.09M
- Free Cash Flow per Share
- -0.60
Dividends & Yields
Pacific Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -33.10%
- Earnings Yield
- -23.17%
Stock Price Statistics
- Beta
- 0.09
- 52-Week Price Change
- 21.10%
- 50-Day Moving Average
- 1.77
- 200-Day Moving Average
- 1.36
- Relative Strength Index (RSI)
- 40.45
- Average Volume (3m)
- 5,426
Important Dates
Pacific Biosciences upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Pacific Biosciences as a current ratio of 6.89, with Debt / Equity ratio of 14206.58%
- Current Ratio
- 6.89
- Quick Ratio
- 5.99
- Debt to Market Cap
- 1.25
- Net Debt to EBITDA
- -4.56
- Interest Coverage Ratio
- -80.18
Taxes
In the past 12 months, Pacific Biosciences has paid 318.00K in taxes.
- Income Tax
- 318.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Pacific Biosciences EV to EBITDA ratio is -10.77, with an EV/FCF ratio of -6.47.
- EV to Sales
- 7.55
- EV to EBITDA
- -10.77
- EV to Free Cash Flow
- -6.47
- EV to Operating Cash Flow
- -6.70
Balance Sheet
Pacific Biosciences has EUR 199.42M in cash and marketable securities with EUR 705.37M in debt, giving a net cash position of -EUR 505.95M billion.
- Cash & Marketable Securities
- EUR 199.42M
- Total Debt
- EUR 705.37M
- Net Cash
- -EUR 505.95M
- Net Cash Per Share
- -EUR 1.62
- Tangible Book Value Per Share
- -EUR 1.26
Margins
Gross margin is 34.51%, with operating margin of -99.59%, and net profit margin of -81.31%.
- Gross Margin
- 34.51%
- Operating Margin
- -99.59%
- Pretax Margin
- -80.87%
- Net Profit Margin
- -81.31%
- EBITDA Margin
- -70.09%
- EBIT Margin
- -78.29%
Analyst Forecast
The average price target for Pacific Biosciences is EUR 2.40, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 2.40
- Price Target Upside
- 45.82% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 5
- Revenue Growth Forecast
- -0.79%
- EPS Growth Forecast
- 76.78%
Scores
- Smart Score
- 6
- AI Score
- ―

